MobiHealthNews

Novartis taps Microsoft for new AI initiative on drug discovery, development

Novartis is teaming up with Microsoft on a new artificial intelligence initiative focused on drug discovery and development. The new efforts will primarily be focused in Novartis’ newly announced AI ...

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

SNV4818 is an oral treatment being evaluated in an early and mid-stage study for breast cancer and other advanced solid ...
NJBIZ

Novartis to acquire Regulus in $1.7B kidney drug deal

Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of $800 ...
GEN

Novartis, ProFound Therapeutics Ink Multi-Year Collaboration to Target Cardiovascular Disease Proteins

Seeking to develop novel medicines for cardiovascular disease, Novartis and ProFound Therapeutics have signed a four-year strategic collaboration. The agreement will allow the partners to combine ...
Fierce Biotech

Novartis pens $2B deal for allergy biotech with potential Xolair successor

Excellergy has been snapped up by the Swiss pharma only five months after emerging with $70 million in funds. The Palo Alto, ...

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than ...
U.S. News & World Report

Novartis Signs up to $5.7 Billion Licensing Deal With Monte Rosa Therapeutics

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the ...
Hosted on MSN

SciNeuro, Novartis strike $1.7B Alzheimer’s drug megadeal

Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a megadeal that signals how aggressively big pharma is now chasing ...
AOL

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of ...
Insider Monkey

Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report

We recently published 13 Best ADR Stocks to Invest In. Novartis AG (NYSE:NVS) is one of the best ADR stocks. Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion ...
BioSpace

Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway

After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other ...
U.S. News & World Report

Novartis to Buy Experimental Breast Cancer Drug in up to $3 Billion Deal

FRANKFURT, March 20 (Reuters) - Swiss drugmaker ⁠Novartis ⁠on Friday agreed to ⁠buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics, adding a ...